Prior Authorization Required

Prior authorization is required for allogeneic hematopoietic cell transplantation (HCT) procedures and associated transplant services. Requests must document that the member meets the transplanting institution's selection criteria; if the institution has no published criteria, documentation must demonstrate that the member meets Aetna's medical necessity criteria for allogeneic HCT.

• Prior authorization required for allogeneic HCT and related CPT/HCPCS codes (see CPT/HCPCS lists).
• Autologous HCT requests for indications listed in this policy are considered investigational and require denial documentation if submitted for those indications.

Prior Authorization: Diagnostic and Donor Documentation

Documentation submitted with prior authorization requests should include diagnostic confirmation, donor availability and HLA status, and other clinically relevant donor information. Where applicable, include telomere length testing and genetic testing to exclude inherited marrow-failure syndromes.

• Documented donor HLA typing (e.g., 86813, 86817, 86920-86923).
• Evidence of donor availability and relationship (matched sibling, unrelated, haploidentical) and graft source (bone marrow, peripheral blood, cord blood).
• Telomere length and genetic testing results when inherited marrow-failure syndromes are suspected.

Diagnostic Workup Expectations

Expected diagnostic workup prior to authorization includes a bone marrow evaluation with cellularity assessment, cytogenetics and FISH to exclude genetic etiologies, complete blood counts and reticulocyte count, and other tests as clinically indicated (e.g., compatibility testing). Results of these studies are often required before initiation of therapy or approval of transplant.

• Bone marrow biopsy/report with cellularity.
• Cytogenetics and specific FISH assays to exclude genetic causes.
• Complete blood count with neutrophil, platelet, and reticulocyte counts (document thresholds when applicable).
• Compatibility and crossmatch testing as appropriate.

Autologous Transplant Considered Investigational

Autologous hematopoietic cell transplantation for severe aplastic anemia and the specified inherited marrow-failure syndromes is considered experimental and investigational; prior authorization submissions for autologous HCT for these indications should be evaluated against this policy and will generally not be approved.

• Autologous transplantation CPT codes (e.g., 38232, 38241) are not covered for indications listed in this CPB.
• Denial rationale should reference lack of established effectiveness for these indications.

Preferred Initial Therapy and Sequence Considerations

Clinical decision-making should reflect age-based and evidence considerations: allogeneic HCT from an HLA-matched sibling donor is generally preferred as initial therapy in younger patients (typically <20 years); for patients >40 years, immunosuppressive therapy (IST) is generally the preferred initial approach and allogeneic transplant is reserved for IST failure, relapse, or other appropriate indications. Comparative effectiveness of first-line matched-sibling HSCT versus first-line IST is uncertain; individual patient factors, donor availability, and institutional expertise should guide sequencing.

• Preferred initial therapy: <20 yrs — allogeneic HCT from HLA-matched related donor.
• Preferred initial therapy: >40 yrs — IST (e.g., ATG + cyclosporine); reserve allogeneic HCT for IST failure or relapse.
• Uncertainty exists comparing first-line matched sibling HSCT vs first-line IST; document rationale for chosen sequence.

Step Therapy

There are no formal step-therapy requirements or sequencing rules imposed by this policy beyond the clinical recommendations above; authorization decisions are based on documented medical necessity, diagnostic workup, donor status, and institutional selection criteria.

• No mandated step-therapy protocols in policy; do not require prior IST trial for young patients when allogeneic HCT with matched sibling donor is clinically indicated.
• Authorization guided by member-specific clinical data rather than automatic sequencing rules.

Required Documentation

Required documentation must show that the member meets the transplanting institution's selection criteria or, if institutional criteria are unavailable, that the member meets Aetna's listed medical necessity criteria for allogeneic HCT. Include prior treatment history, response to IST when relevant, and indication-specific clinical details.

• Transplant center selection criteria or statement that institutional criteria were applied.
• Clinical history including prior therapies (e.g., IST), response or failure, transfusion dependence, and complications.
• Specific indication documentation (e.g., diagnostic thresholds for severe aplastic anemia: marrow cellularity, neutrophil, platelet, reticulocyte counts).

Required Clinical Documentation

Required clinical documentation includes bone marrow evaluation reports, cytogenetic/FISH results, telomere length or genetic testing when relevant, donor HLA status and compatibility testing, and transplant candidacy assessments (age, comorbidities, prior therapies). These items support medical necessity determinations.

• Bone marrow biopsy and cellularity report.
• Cytogenetics and FISH assay results.
• Telomere length testing when inherited syndromes suspected.
• Donor HLA typing and compatibility tests (e.g., 86813, 86817, 86920-86923).
• Documentation of graft source and donor type.

No Explicit Denial Triggers Specified

This policy does not enumerate specific denial triggers beyond the investigational status of autologous HCT for the listed indications and failure to meet medical necessity or documentation requirements. Denials should be based on absence of required clinical criteria, investigational status where applicable, or lack of necessary diagnostic/donor documentation.

• No other explicit automatic denial triggers are listed in the policy.
• Common denial reasons: insufficient diagnostic data, missing donor/HLA information, autologous HCT requested for investigational indications.

Supplemental Documentation Links

Supplemental resources and links that should accompany authorization and clinical review processes include the policy review history, definitions, and Clinical Policy Bulletin Notes. Use these resources for administrative guidance and definitions relevant to coverage determinations.

• Include links or references to: Review History, Definitions, and Clinical Policy Bulletin Notes when submitting or adjudicating requests.
• Reference policy effective date and last review (Effective: 06/28/2002; Last Review: 09/12/2023) as needed.